Beta

Adicet bio, inc.ACET.US Overview

US StockHealthcare
(No presentation for ACET)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ACET AI Insights

ACET Overall Performance

ACET AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ACET Recent Performance

-3.28%

Adicet bio, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ACET PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ACET's Trend

ACET Key Information

ACET Valuation Metrics

ACET Profile

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Price of ACET

ACET FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-12.17
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.72
PB Ratio
0.48
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-12.17
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.72
PB Ratio
0.48
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ACET's latest earnings report released?

    The most recent financial report for Adicet bio, inc. (ACET) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACET's short-term business performance and financial health. For the latest updates on ACET's earnings releases, visit this page regularly.

  • How much debt does ACET have?

    As of the end of the reporting period, Adicet bio, inc. (ACET) had total debt of 14.74M, with a debt ratio of 0.08. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ACET have?

    At the end of the period, Adicet bio, inc. (ACET) held Total Cash and Cash Equivalents of 41.79M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ACET's EPS continuing to grow?

    According to the past four quarterly reports, Adicet bio, inc. (ACET)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.95. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ACET?

    Adicet bio, inc. (ACET)'s Free Cash Flow (FCF) for the period is -20.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ACET?

    The latest valuation data shows Adicet bio, inc. (ACET) has a Price-To-Earnings (PE) ratio of -0.58 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

ACET Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1